Our approach combines biological data from HER2 tissue-based biomarkers, which reflects the tumor's molecular characteristics and potential for response to HER2-targeted therapy, with functional information from PET imaging which assesses metabolic activity and monitors dynamic response to therapy in real time, with the aim of creating a personalized predictive tool. This evidence concerns the gene ERBB2 and neoplasm.